Qiu Yun, Wu Yichen, Zhao Hongmei, Sun Hong, Gao Sumin
Department of Emergency Medicine, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu Province, China,
Drug Des Devel Ther. 2019 Feb 20;13:739-745. doi: 10.2147/DDDT.S188654. eCollection 2019.
Inflammation and oxidative stress play a crucial role in the pathogenesis of renal ischemia/reperfusion injury (IRI). Maresin 1 (MaR1), which has shown strong anti-inflammatory and antioxidant effects, was recently reported to have protective properties in several different animal models.
The objectives of our study were to determine whether MaR1 alleviates renal IRI and to identify the underlying mechanisms.
The mouse model in this study was induced by ischemia of the left kidney for 45 minutes and by nephrectomy of the right kidney. All mice were intravenously injected with a vehicle or MaR1. Renal histopathologic changes, function, proinflammatory cytokines, and oxidative stress were assessed. The expression of proteins was measured by Western blot.
The results indicated that MaR1 markedly protected against renal IRI. The protective effects were accompanied by the reduction of histologic changes and reduction of renal dysfunction. Meanwhile, MaR1 remarkably mitigated renal IRI-induced inflammation and oxidative stress. In addition, our results showed that MaR1 significantly inhibited the expression of TLR4 and the expression of phosphorylated Erk, JNK, and P38. Furthermore, MaR1 decreased the nuclear translocation of NF-κB and increased the nuclear translocation of Nrf2.
MaR1 protects against renal IRI by inhibiting the TLR4/MAPK/NF-κB pathways, which mediate anti-inflammation, and by activating the Nrf2 pathway, which mediates antioxidation.
炎症和氧化应激在肾缺血/再灌注损伤(IRI)的发病机制中起关键作用。maresin 1(MaR1)已显示出强大的抗炎和抗氧化作用,最近有报道称其在几种不同的动物模型中具有保护特性。
我们研究的目的是确定MaR1是否能减轻肾IRI,并确定其潜在机制。
本研究中的小鼠模型通过左肾缺血45分钟和右肾切除诱导。所有小鼠静脉注射载体或MaR1。评估肾组织病理学变化、功能、促炎细胞因子和氧化应激。通过蛋白质印迹法测量蛋白质表达。
结果表明,MaR1对肾IRI具有显著的保护作用。保护作用伴随着组织学变化的减少和肾功能障碍的减轻。同时,MaR1显著减轻了肾IRI诱导的炎症和氧化应激。此外,我们的结果表明,MaR1显著抑制TLR4的表达以及磷酸化Erk、JNK和P38的表达。此外,MaR1减少了NF-κB的核转位并增加了Nrf2的核转位。
MaR1通过抑制介导抗炎作用的TLR4/MAPK/NF-κB途径和激活介导抗氧化作用的Nrf2途径来保护肾IRI。